Nivolumab outperformed the drug brentuximab vedotin (Adcetris), extending progression-free survival by 94% to one year versus 86%. Photo by Erubiel Flores/Pixabay The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard of care, new clinical trial results show. Nivolumab outperformed the drug brentuximab vedotin (Adcetris), extending progression-free survival by 94% to one year versus 86%. Advertising Nivolumab also produced significantly fewer side effects than brentuximab vedotin, which was the first new…
Read MoreTag: Lymphoma
Nivolumab with AVD Provides PFS Benefit Compared to Brentuximab Vedotin Plus AVD in Advanced Hodgkin Lymphoma
Treatment with nivolumab (Opdivo) combined with doxorubicin, vinblastine, and dacarbazine (AVD) resulted in prolonged progression-free survival (PFS) compared with brentuximab vedotin (Adcetris) plus AVD in patients with advanced-stage classic Hodgkin lymphoma (cHL ), according to the results of the Phase 3SWOG S1826 study (NCT03907488) presented at the 2023 ASCO Annual Meeting. At a median follow-up of 12.1 months, results showed that patients who received nivolumab plus AVD (n = 489) experienced an estimated 1-year PFS rate of 94% (95% CI, 91% -96%) versus 86% (95% CI, 82%-90%) among patients treated…
Read More